Evaluation of the SIGNIFY trial

Research output: Contribution to journalArticle

Abstract

A reduction in the heart rate has been thought to be beneficial in coronary artery disease. The study assessing the morbidity-mortality Benefits of the If Inhibitor, Ivabradine, in patients with coronary artery disease (SIGNIFY) tested this hypothesis. It specifically evaluated the effects of ivabradine, administered at the dosage of 5-10 mg/bid in addition to current drug treatment, on cardiovascular outcome in 19102 patients with heart rate ≥ 70 bpm in normal sinus rhythm and stable coronary artery disease without heart failure. The primary endpoint of the trial, whose follow-up averaged for 2.3 years, was a composite of death from cardiovascular causes or nonfatal myocardial infarction whereas the secondary endpoint was represented by the primary endpoint plus total mortality. The incidence of the primary endpoint was at the study end similar in the ivabradine-treated and in the placebo-treated group (6.8 vs 6.4%, p = NS). Superimposable was also the incidence of death for cardiovascular events and for nonfatal myocardial infarction. However, in the 12049 patients with angina class II or higher ivabradine significantly increased the incidence of primary endpoint as compared to placebo (7.6 vs 6.5%, p <0.02). This was associated with a significantly greater incidence of bradycardia, atrial fibrillation and Q-T prolongation. Taken together the results of the SIGNIFY do not support the clinical benefits of ivabradine in patients with stable coronary artery disease.

Original languageEnglish
Pages (from-to)1861-1864
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number12
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

ivabradine
Coronary Artery Disease
Incidence
Heart Rate
Myocardial Infarction
Placebos
Mortality
Bradycardia
Atrial Fibrillation
Cause of Death
Heart Failure
Morbidity

Keywords

  • atrial fibrillation
  • coronary artery disease
  • heart rate
  • ivabradine
  • J curve

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Evaluation of the SIGNIFY trial. / Grassi, Guido.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 12, 01.08.2015, p. 1861-1864.

Research output: Contribution to journalArticle

@article{7d516d112afa47d489ba281a7506a989,
title = "Evaluation of the SIGNIFY trial",
abstract = "A reduction in the heart rate has been thought to be beneficial in coronary artery disease. The study assessing the morbidity-mortality Benefits of the If Inhibitor, Ivabradine, in patients with coronary artery disease (SIGNIFY) tested this hypothesis. It specifically evaluated the effects of ivabradine, administered at the dosage of 5-10 mg/bid in addition to current drug treatment, on cardiovascular outcome in 19102 patients with heart rate ≥ 70 bpm in normal sinus rhythm and stable coronary artery disease without heart failure. The primary endpoint of the trial, whose follow-up averaged for 2.3 years, was a composite of death from cardiovascular causes or nonfatal myocardial infarction whereas the secondary endpoint was represented by the primary endpoint plus total mortality. The incidence of the primary endpoint was at the study end similar in the ivabradine-treated and in the placebo-treated group (6.8 vs 6.4{\%}, p = NS). Superimposable was also the incidence of death for cardiovascular events and for nonfatal myocardial infarction. However, in the 12049 patients with angina class II or higher ivabradine significantly increased the incidence of primary endpoint as compared to placebo (7.6 vs 6.5{\%}, p <0.02). This was associated with a significantly greater incidence of bradycardia, atrial fibrillation and Q-T prolongation. Taken together the results of the SIGNIFY do not support the clinical benefits of ivabradine in patients with stable coronary artery disease.",
keywords = "atrial fibrillation, coronary artery disease, heart rate, ivabradine, J curve",
author = "Guido Grassi",
year = "2015",
month = "8",
day = "1",
doi = "10.1517/14656566.2015.1059423",
language = "English",
volume = "16",
pages = "1861--1864",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Evaluation of the SIGNIFY trial

AU - Grassi, Guido

PY - 2015/8/1

Y1 - 2015/8/1

N2 - A reduction in the heart rate has been thought to be beneficial in coronary artery disease. The study assessing the morbidity-mortality Benefits of the If Inhibitor, Ivabradine, in patients with coronary artery disease (SIGNIFY) tested this hypothesis. It specifically evaluated the effects of ivabradine, administered at the dosage of 5-10 mg/bid in addition to current drug treatment, on cardiovascular outcome in 19102 patients with heart rate ≥ 70 bpm in normal sinus rhythm and stable coronary artery disease without heart failure. The primary endpoint of the trial, whose follow-up averaged for 2.3 years, was a composite of death from cardiovascular causes or nonfatal myocardial infarction whereas the secondary endpoint was represented by the primary endpoint plus total mortality. The incidence of the primary endpoint was at the study end similar in the ivabradine-treated and in the placebo-treated group (6.8 vs 6.4%, p = NS). Superimposable was also the incidence of death for cardiovascular events and for nonfatal myocardial infarction. However, in the 12049 patients with angina class II or higher ivabradine significantly increased the incidence of primary endpoint as compared to placebo (7.6 vs 6.5%, p <0.02). This was associated with a significantly greater incidence of bradycardia, atrial fibrillation and Q-T prolongation. Taken together the results of the SIGNIFY do not support the clinical benefits of ivabradine in patients with stable coronary artery disease.

AB - A reduction in the heart rate has been thought to be beneficial in coronary artery disease. The study assessing the morbidity-mortality Benefits of the If Inhibitor, Ivabradine, in patients with coronary artery disease (SIGNIFY) tested this hypothesis. It specifically evaluated the effects of ivabradine, administered at the dosage of 5-10 mg/bid in addition to current drug treatment, on cardiovascular outcome in 19102 patients with heart rate ≥ 70 bpm in normal sinus rhythm and stable coronary artery disease without heart failure. The primary endpoint of the trial, whose follow-up averaged for 2.3 years, was a composite of death from cardiovascular causes or nonfatal myocardial infarction whereas the secondary endpoint was represented by the primary endpoint plus total mortality. The incidence of the primary endpoint was at the study end similar in the ivabradine-treated and in the placebo-treated group (6.8 vs 6.4%, p = NS). Superimposable was also the incidence of death for cardiovascular events and for nonfatal myocardial infarction. However, in the 12049 patients with angina class II or higher ivabradine significantly increased the incidence of primary endpoint as compared to placebo (7.6 vs 6.5%, p <0.02). This was associated with a significantly greater incidence of bradycardia, atrial fibrillation and Q-T prolongation. Taken together the results of the SIGNIFY do not support the clinical benefits of ivabradine in patients with stable coronary artery disease.

KW - atrial fibrillation

KW - coronary artery disease

KW - heart rate

KW - ivabradine

KW - J curve

UR - http://www.scopus.com/inward/record.url?scp=84937700581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937700581&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1059423

DO - 10.1517/14656566.2015.1059423

M3 - Article

C2 - 26153241

AN - SCOPUS:84937700581

VL - 16

SP - 1861

EP - 1864

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -